These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 12096169)

  • 1. Service use and costs among VA patients with schizophrenia taking risperidone or olanzapine.
    Fuller MA; Shermock KM; Secic M; Laich JS; Durkin MB
    Psychiatr Serv; 2002 Jul; 53(7):855-60. PubMed ID: 12096169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost evaluation of risperidone compared with olanzapine.
    Byerly MJ; Weber M; Brooks D; Casey SB; Elliot S; Hawkins J
    Psychiatr Serv; 2003 May; 54(5):742-4. PubMed ID: 12719509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of co-morbidities with prescribing patterns and cost savings: olanzapine versus risperidone for schizophrenia.
    Yu W; Ren XS; Lee AF; Herz L; Huang YH; Kazis LE
    Pharmacoeconomics; 2006; 24(12):1233-48. PubMed ID: 17129077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of atypical antipsychotics in a Veterans Affairs hospital.
    Schwartz TL; Saba M; Hardoby W; Virk S; Masand PS
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Oct; 26(6):1207-10. PubMed ID: 12452548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients.
    Rascati KL; Johnsrud MT; Crismon ML; Lage MJ; Barber BL
    Pharmacoeconomics; 2003; 21(10):683-97. PubMed ID: 12828491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia.
    Zhao Z
    Manag Care Interface; 2002 Feb; 15(2):75-81. PubMed ID: 11875967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.
    Taylor DM; Wright T; Libretto SE;
    J Clin Psychiatry; 2003 May; 64(5):589-97. PubMed ID: 12755664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of risperidone and olanzapine in outpatient clinics at six Veterans Affairs hospitals.
    Voris JC; Glazer WM
    Psychiatr Serv; 1999 Feb; 50(2):163-4, 168. PubMed ID: 10030472
    [No Abstract]   [Full Text] [Related]  

  • 9. [RODOS: risperidone olanzapine drug outcome studies in schizophrenia].
    De Beauchamp I; Giraud-Baro E; Gury C
    Encephale; 2002; 28 Spec No 2 Pt 2():S33-4. PubMed ID: 12587356
    [No Abstract]   [Full Text] [Related]  

  • 10. Initiation of atypical antipsychotic agents and health outcomes in patients with schizophrenia.
    Ren XS; Lee AF; Huang YH; Hamed A; Herz L; Miller DR; Kazis LE
    J Clin Pharm Ther; 2004 Oct; 29(5):471-81. PubMed ID: 15482392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.
    Gibson PJ; Damler R; Jackson EA; Wilder T; Ramsey JL
    Value Health; 2004; 7(1):22-35. PubMed ID: 14720128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.
    Mladsi DM; Grogg AL; Irish WD; Lopez RB; Degen K; Swann A; Nimsch CT
    Curr Med Res Opin; 2004 Dec; 20(12):1883-93. PubMed ID: 15701206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient characteristics and the likelihood of initiation on olanzapine or risperidone among patients with schizophrenia.
    Ren XS; Kazis LE; Lee AF; Huang YH; Hamed A; Cunningham F; Herz L; Miller DR
    Schizophr Res; 2005 Sep; 77(2-3):167-77. PubMed ID: 15894460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic outcomes associated with olanzapine versus risperidone in the treatment of uncontrolled schizophrenia.
    Zhao Z
    Curr Med Res Opin; 2004 Jul; 20(7):1039-48. PubMed ID: 15265249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia.
    Edgell ET; Andersen SW; Johnstone BM; Dulisse B; Revicki D; Breier A
    Pharmacoeconomics; 2000 Dec; 18(6):567-79. PubMed ID: 11227395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health care costs for schizophrenia patients started on olanzapine versus risperidone.
    Russo PA; Smith MW; Namjoshi M
    Am J Health Syst Pharm; 2005 Mar; 62(6):610-5. PubMed ID: 15757882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine.
    Kelly DL; Nelson MW; Love RC; Yu Y; Conley RR
    Psychiatr Serv; 2001 May; 52(5):676-8. PubMed ID: 11331805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration.
    Ren XS; Crivera C; Sikirica M; Dirani R; Qian S; Kazis LE
    J Clin Pharm Ther; 2011 Jun; 36(3):383-9. PubMed ID: 21062329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cost-effectiveness clinical decision analysis model for treatment of Schizophrenia.
    Palmer CS; Brunner E; Ruíz-Flores LG; Paez-Agraz F; Revicki DA
    Arch Med Res; 2002; 33(6):572-80. PubMed ID: 12505105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
    Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V;
    JAMA; 2003 Nov; 290(20):2693-702. PubMed ID: 14645311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.